Merck (MRK) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.13
- EPS estimate
- −$0.27
- EPS surprise
- +51.42%
- Revenue surprise
- +1.45%
- Revenue
- $16.6B
- Revenue estimate
- $16.4B
- Reported
- Aug 4, 2026
Merck reported Q2 2026 results on August 4, 2026. It posted a loss of $0.13 per share, narrower than the expected loss of $0.27, a 51.42% beat. Revenue was $16.6 billion, ahead of the $16.4 billion estimate by 1.45%. A year earlier, in Q2 2025, Merck earned $2.13 per share on revenue of $15.8 billion, so revenue rose about 5% while EPS swung to a loss.
This is the second loss in a row, after a $1.28 per share loss in Q1 2026. The first half of 2026 totals a loss of $1.41 per share, against earnings of $4.35 in the first half of 2025, while revenue rose about 5% to $32.9 billion. Annual EPS was $7.48 in 2022, $1.50 in 2023, $7.64 in 2024 and $8.97 in 2025. Q2 2023's loss of $2.06 is the low in the table. The high was Q3 2025, at $2.58 per share and $17.3 billion in revenue. Merck beat EPS estimates in all 20 quarters.
Merck reported Q3 between October 26 and October 31 in each of the last five years. That points to late October 2026 for the next report. It will show whether Merck returns to a profit after two losses.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 4, 2026 | −$0.27 | −$0.13 | +51.42% | $16.6B | SEC |
| Q1 2026 | Apr 30, 2026 | −$1.47 | −$1.28 | +13.15% | $16.3B | SEC |
| Q4 2025 | Feb 3, 2026 | $2.01 | $2.04 | +1.43% | $16.4B | SEC |
| Q3 2025 | Oct 30, 2025 | $2.36 | $2.58 | +9.21% | $17.3B | SEC |
| Q2 2025 | Jul 29, 2025 | $2.03 | $2.13 | +4.77% | $15.8B | SEC |
| Q1 2025 | Apr 24, 2025 | $2.13 | $2.22 | +4.09% | $15.5B | SEC |
| Q4 2024 | Feb 4, 2025 | $1.61 | $1.72 | +6.88% | $15.6B | SEC |
| Q3 2024 | Oct 31, 2024 | $1.48 | $1.57 | +5.80% | $16.7B | SEC |
| Q2 2024 | Jul 30, 2024 | $2.17 | $2.28 | +5.17% | $16.1B | SEC |
| Q1 2024 | Apr 25, 2024 | $1.89 | $2.07 | +9.79% | $15.8B | SEC |
| Q4 2023 | Feb 1, 2024 | −$0.11 | $0.03 | +127.65% | $14.6B | SEC |
| Q3 2023 | Oct 26, 2023 | $1.95 | $2.13 | +9.04% | $16.0B | SEC |
| Q2 2023 | Aug 1, 2023 | −$2.18 | −$2.06 | +5.53% | $15.0B | SEC |
| Q1 2023 | Apr 27, 2023 | $1.32 | $1.40 | +5.96% | $14.5B | SEC |
| Q4 2022 | Feb 2, 2023 | $1.53 | $1.62 | +5.54% | $13.8B | SEC |
| Q3 2022 | Oct 27, 2022 | $1.71 | $1.85 | +8.47% | $15.0B | — |
| Q2 2022 | Jul 28, 2022 | $1.70 | $1.87 | +9.74% | $14.6B | — |
| Q1 2022 | Apr 28, 2022 | $1.83 | $2.14 | +17.23% | $15.9B | — |
| Q4 2021 | Feb 3, 2022 | $1.53 | $1.80 | +17.93% | $13.5B | — |
| Q3 2021 | Oct 28, 2021 | $1.55 | $1.75 | +13.21% | $13.2B | — |
Quarterly revenue
Frequently asked questions
When did Merck (MRK) last report earnings?
Merck last reported on Aug 4, 2026, covering fiscal Q2 2026.
Did MRK beat earnings estimates?
Yes. Merck reported EPS of −$0.13 for Q2 2026 against a −$0.27 estimate — a 51.42% beat.
How much revenue did MRK report last quarter?
Merck reported $16.6B in revenue for Q2 2026, against a consensus estimate of $16.4B.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.